Clinical data suggest the role of L-DOPA in Alzheimer's Disease (AD) though its mechanism of action in AD is not clear. Previous results suggest that L-DOPA might have a complex mixture of pro- and antioxidant effects contributing to tissue damage due to oxidative stress. Furthermore, entacapone, a COMT inhibitor, is known to retain greater levodopa levels in plasma during coadministration. Hence, the role of L-DOPA + entacapone in aluminum induced oxidative stress in the rat brain was evaluated. Sprague Dawley rats (n = 6/group) were treated with either the vehicle, aluminum, L-DOPA + entacapone or aluminum + L-DOPA + entacapone for 28 days. The intact brains were processed for lipid peroxidation (LPO) and superoxide dismutase (SOD) activity. Aluminum treatment showed highly elevated levels of LPO while the combination of L-DOPA and entacapone could not control this oxidative burst in the rat brains both in presence and absence of aluminum. No change was observed in the brain or the circulating SOD activity. Hence, it is derived that protective role of L-DOPA in AD management is not exerted through its antioxidant property and may be manifested due to its involvement in other pathways.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Two years' experience with levodopa-entacapone-carbidopa intestinal gel treatment in advanced Parkinson's disease].
Orv Hetil
January 2025
1 Universitatea de Medicină, Farmacie, Științe și Tehnologie "George Emil Palade" din Târgu Mures (Marosvásárhelyi George Emil Palade Orvosi, Gyógyszerészeti, Tudomány és Technológiai Egyetem) Marosvásárhely, Gral Ion Dumitrache u. 20/A, 540081 Romania.
Long-term effect and reasons for switching and combining device-aided therapies in Parkinson's Disease.
Neurol Neurochir Pol
January 2025
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Introduction: In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.
Aim Of Study: The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.
Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.
Brain Sci
December 2024
Hospital Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain.
Background And Objective: Staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (Motor; Non-motor; Cognition; Dependency) and five stages, correlated with disease severity, patients' quality of life and caregivers' strain and burden. Our aim was to apply the MNCD classification in advanced PD patients treated with device-aided therapy (DAT).
Patients And Methods: A multicenter observational retrospective study of the first patients to start the levodopa-entacapone-carbidopa intestinal gel (LECIG) in Spain was performed (LECIPARK study).
How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis.
Eur J Neurol
January 2025
Parkinson and Movement Disorders Unit, Study Center for Neurodegenerative diseases (CESNE), Department of Neuroscience, Padua Neuroscience Center (PNC), University of Padua, Padua, Italy.
Background: Parkinson's disease (PD) is a neurodegenerative disorder affecting both sexes, but differences exist between male and female in clinical manifestations, functional impact of symptoms and hormonal influences. Therefore, representativeness of females in PD trials indirectly determines the external validity of the clinical research in this field.
Objective: To estimate the representativeness of female in infusion therapy trials for advanced PD.
Challenges of equitable access to device-aided therapies for advanced Parkinson's Disease in Poland - expert consensus and treatment recommendations.
Neurol Neurochir Pol
December 2024
Department of Neurological-Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.
Introduction: In Poland, not all forms of device-aided therapies for advanced Parkinson's Disease (APD) are currently available.
Material And Methods: We aimed to produce a consensus recommendation from Polish movement disorders experts after discussing gaps in the APD care pathway in Poland.
Results: Rescue therapy with apomorphine (APO) PEN injection and levodopa-entacapone-carbidopa intestinal gel infusion are not included in Poland's Specialist Therapeutic Programme, and are thus not reimbursed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!